Biopolitics, Mythic Science, and Progressive Values
By Marcy Darnovsky,
Progress in Bioethics: Science, Policy and Politics; edited by Jonathan D. Moreno and Sam Berger (The MIT Press, 2010)
| 10. 16. 2009
When bioethical deliberation confronts human biotechnologies, it often faces novel questions that recent technical developments have conjured into existence. Many of these biotechnology-related situations are both socially consequential and, at least in some respects, unprecedented in human experience. After spending its first years considering these issues largely as a scholarly endeavor with practical applications in human research and medical practice, bioethics in recent years has ventured far beyond academic and clinical settings.
Among the bioethical issues that have of late become topical are cloning and stem cell research; regulation of the assisted reproduction industry; "designer babies" and the prospect of a market-driven "techno-eugenics;" sex selection and disability de-selection; surrogacy and reproductive tourism; patents on life and markets in kidneys, eggs, and other human tissue. Formerly the province of philosophers, physicians, and lawyers, these topics are now frequently discussed in mainstream media, popular culture and electoral politics. They are matters of interest to entrepreneurs, venture capitalists, and global industries. They have captured the attention of policy makers, political consultants, and candidates; of philosophers, ministers, and rabbis. They are subjects for social...
Related Articles
By Peter Wehling, Tino Plümecke, and Isabelle Bartram
| 03.26.2025
This article was originally published as “Soziogenomik und polygene Scores” in issue 272 (February 2025) of the German-language journal Gen-ethischer Informationsdienst (GID); translated by the authors.
In mid-November 2024, the British organization Hope not Hate published its investigative research ‘Inside the Eugenics Revival’. In addition to documentating an active international “race research” network, the investigation also brought to light the existence of a US start-up that offers eugenic embryo selection. Heliospect Genomics aims to enable wealthy couples to...
After almost 20 years of publicity stunts and dubious claims, we may not have 23andMe to kick around anymore. The company has filed for Chapter 11 bankruptcy protection. The stock has collapsed to about 2% of its peak value. CEO and co-founder Anne Wojcicki has quit (though she may be baaack) and the company’s future, if any, depends on its DNA database.
Note to customers of the company: Get Out. Cybersecurity expert Adrianus Warmenhoven told the Associated Press...
By ACLU Northern California
| 03.21.2025
In a long-standing lawsuit, the ACLU, on behalf of partner organizations and an individual taxpayer, is challenging the state of California for its retention of genetic samples and profiles from people arrested but never convicted of a felony.
The complaint...
By Loren Johnston, Portland Press Herald | 03.15.2025